合計 50 件の最近のインサイダー取引記録が記録されています Zosano Pharma Corporation (ZSAN), 内訳は 38 件の買い および 11 件の売り. インサイダー買い総額は $5.29M インサイダー売り総額は $38.93K.
最近活動のある主要インサイダーには Lo Steven, Matthews Christine, Kellerman Donald J. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — ZSAN
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2022-06-06 |
Lo Steven |
Chief Executive Officer |
情報に基づく売り |
442 |
$0.71 |
$313.82 |
13,163 |
| 2022-06-06 |
Matthews Christine |
Chief Financial Officer |
情報に基づく売り |
82 |
$0.71 |
$58.22 |
4,183 |
| 2022-03-31 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
情報に基づく売り |
4,006 |
$0.21 |
$841.66 |
56,331 |
| 2022-03-31 |
Lo Steven |
Chief Executive Officer |
情報に基づく売り |
23,633 |
$0.21 |
$4.97K |
460,709 |
| 2022-03-31 |
Matthews Christine |
Chief Financial Officer |
情報に基づく売り |
8,116 |
$0.21 |
$1.71K |
146,425 |
| 2021-11-23 |
Greathouse Kenneth |
Director |
情報に基づく売り |
10,000 |
$0.60 |
$6.02K |
43,500 |
| 2021-10-15 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU 付与(制限付株式) |
20,000 |
$0.63 |
$12.68K |
20,000 |
| 2021-10-15 |
Lo Steven |
Chief Executive Officer |
RSU 付与(制限付株式) |
237,500 |
$0.63 |
$150.62K |
237,500 |
| 2021-10-15 |
Matthews Christine |
Chief Financial Officer |
RSU 付与(制限付株式) |
112,500 |
$0.63 |
$71.35K |
112,500 |
| 2021-06-10 |
Greathouse Kenneth |
Director |
RSU 付与(制限付株式) |
30,000 |
$0.93 |
$27.95K |
30,000 |
| 2021-06-10 |
Elms Steve |
Director |
RSU 付与(制限付株式) |
15,000 |
- |
- |
22,500 |
| 2021-06-10 |
Xanthopoulos Kleanthis G |
Director |
RSU 付与(制限付株式) |
15,000 |
- |
- |
23,596 |
| 2021-06-10 |
Hagan Joseph P |
Director |
RSU 付与(制限付株式) |
15,000 |
- |
- |
22,500 |
| 2021-06-04 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
情報に基づく売り |
1,709 |
$0.81 |
$1.38K |
50,337 |
| 2021-06-04 |
Lo Steven |
Chief Executive Officer |
情報に基づく売り |
13,158 |
$0.81 |
$10.59K |
365,592 |
| 2021-06-04 |
Lewis Hayley |
See Remarks |
情報に基づく売り |
1,709 |
$0.81 |
$1.38K |
49,779 |
| 2021-06-04 |
Matthews Christine |
Chief Financial Officer |
情報に基づく売り |
1,709 |
$0.81 |
$1.38K |
98,291 |
| 2021-05-17 |
Greathouse Kenneth |
Director |
RSU 付与(制限付株式) |
21,000 |
$0.73 |
$15.31K |
38,500 |
| 2021-03-30 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU 付与(制限付株式) |
32,500 |
- |
- |
52,046 |
| 2021-03-30 |
Lo Steven |
Chief Executive Officer |
RSU 付与(制限付株式) |
232,500 |
- |
- |
378,750 |
| 2021-03-30 |
Lewis Hayley |
See Remarks |
RSU 付与(制限付株式) |
32,500 |
- |
- |
51,488 |
| 2021-03-30 |
Matthews Christine |
Chief Financial Officer |
RSU 付与(制限付株式) |
81,250 |
- |
- |
100,000 |
| 2021-03-18 |
Lo Steven |
Chief Executive Officer |
RSU 付与(制限付株式) |
450,000 |
$1.37 |
$616.5K |
450,000 |
| 2020-06-25 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU 付与(制限付株式) |
18,750 |
- |
- |
19,546 |
| 2020-06-25 |
Greathouse Kenneth |
Director |
RSU 付与(制限付株式) |
7,500 |
- |
- |
17,500 |
| 2020-06-25 |
Walker John Peter |
Director |
RSU 付与(制限付株式) |
7,500 |
- |
- |
116,511 |
| 2020-06-25 |
Elms Steve |
Director |
RSU 付与(制限付株式) |
7,500 |
- |
- |
7,500 |
| 2020-06-25 |
Xanthopoulos Kleanthis G |
Director |
RSU 付与(制限付株式) |
7,500 |
- |
- |
8,596 |
| 2020-06-25 |
Hagan Joseph P |
Director |
RSU 付与(制限付株式) |
7,500 |
- |
- |
7,500 |
| 2020-06-25 |
Lo Steven |
Chief Executive Officer |
RSU 付与(制限付株式) |
146,250 |
- |
- |
146,250 |
| 2020-06-25 |
Lewis Hayley |
See Remarks |
RSU 付与(制限付株式) |
18,750 |
- |
- |
18,988 |
| 2020-06-25 |
Matthews Christine |
Chief Financial Officer |
RSU 付与(制限付株式) |
18,750 |
- |
- |
18,750 |
| 2020-06-03 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU 付与(制限付株式) |
37,500 |
$1.01 |
$37.88K |
37,500 |
| 2020-06-03 |
Greathouse Kenneth |
Director |
RSU 付与(制限付株式) |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Walker John Peter |
Director |
RSU 付与(制限付株式) |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Elms Steve |
Director |
RSU 付与(制限付株式) |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Xanthopoulos Kleanthis G |
Director |
RSU 付与(制限付株式) |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Hagan Joseph P |
Director |
RSU 付与(制限付株式) |
15,000 |
$1.01 |
$15.15K |
15,000 |
| 2020-06-03 |
Lo Steven |
Chief Executive Officer |
RSU 付与(制限付株式) |
292,500 |
$1.01 |
$295.43K |
292,500 |
| 2020-06-03 |
Lewis Hayley |
See Remarks |
RSU 付与(制限付株式) |
37,500 |
$1.01 |
$37.88K |
37,500 |
| 2020-06-03 |
Matthews Christine |
Chief Financial Officer |
RSU 付与(制限付株式) |
37,500 |
$1.01 |
$37.88K |
37,500 |
| 2020-05-01 |
Matthews Christine |
Chief Financial Officer |
RSU 付与(制限付株式) |
35,000 |
$0.70 |
$24.54K |
35,000 |
| 2020-02-03 |
Matthews Christine |
See Remarks |
処分 |
3,750 |
$2.75 |
$10.31K |
- |
| 2019-12-02 |
Aisling Capital Iv, Lp |
10 Percent Owner |
RSU 付与(制限付株式) |
689,655 |
$1.45 |
$1000K |
2,718,226 |
| 2019-10-21 |
Lo Steven |
Chief Executive Officer |
不明 |
- |
- |
- |
- |
| 2019-10-21 |
Lo Steven |
Chief Executive Officer |
RSU 付与(制限付株式) |
450,000 |
$1.94 |
$873K |
450,000 |
| 2019-06-11 |
Kellerman Donald J |
VP, Clinical Dev & Med Affairs |
RSU 付与(制限付株式) |
30,000 |
$2.75 |
$82.5K |
30,000 |
| 2019-06-11 |
Lewis Hayley |
See Remarks |
RSU 付与(制限付株式) |
30,000 |
$2.75 |
$82.5K |
30,000 |
| 2019-04-11 |
Aisling Capital Iv, Lp |
10 Percent Owner |
RSU 付与(制限付株式) |
428,571 |
$3.50 |
$1.5M |
2,028,571 |
| 2019-04-11 |
Walker John Peter |
President & CEO |
情報に基づく買い |
100,000 |
$3.50 |
$350K |
280,228 |
■ 情報付き — 公開市場取引(最も重要)
■ 情報なし(買い) — 報酬・オプション行使・転換
■ 情報なし(売り) — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効